Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

August 31, 2002

Study Completion Date

October 31, 2007

Conditions

Prostate Cancer

Interventions

BIOLOGICAL

recombinant fowlpox-prostate specific antigen vaccine

BIOLOGICAL

recombinant vaccinia prostate-specific antigen vaccine

BIOLOGICAL

recombinant vaccinia-B7.1 vaccine

BIOLOGICAL

sargramostim

DRUG

docetaxel

Trial Locations (1)

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00045227 - Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter